Advertisement

Infection

, Volume 24, Issue 2, pp 203–207 | Cite as

Lyme disease vaccine

  • G. P. Wormser
Special Addendum — Part II Therapy And Prophylaxis In Lyme Borreliosis

Summary

Subunit vaccines consisting of single recombinant outer surface proteins (Osp) ofBorrelia burgdorferi have been highly successful in protecting mice against challenge by borrelial strains closely related to the strain from which the immunogen was derived. Humoral immunity is sufficient for protection. A dual mode of action for these vaccines has been suggested because serum factors ingested by the tick during the blood meal may begin to reduce the spirochete inoculum prior to transmission to the host. At present two different recombinant OspA vaccine preparations (monovalent) are being evaluated in humans in large-scale phase III efficacy trials in the United States. Local discomfort at the intramuscular injection site has been the principal adverse effect seen to date with these vaccines, but further data on safety are being collected. The greater heterogeneity of OspA among LymeBorrelia in Europe implies that a vaccine preparation containing multiple antigens (multivalent) may be necessary there, although this is also a concern in the United States.

Keywords

Blood Meal Lyme Disease Subunit Vaccine Vaccine Preparation Outer Surface Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Impfstoffe gegen Lyme-Krankheit

Zusammenfassung

Subunit-Vakzinen, die aus einzelnen rekombinanten Oberflächenproteinen (Osp) vonBorrelia burgdorferi bestehen, führten bei Mäusen zu einem sehr wirksamen Schutz gegen die Infektion mit Borrelienstämmen, die nahe Verwandtschaft mit dem für den Impfstoff verwendeten Stamm haben. Humorale Immunität erwies sich als ausreichend protektiv. Man hat angenommen, daß diese Impfstoffe eine doppelte Wirkung haben, da Serumfaktoren, die die Zecken während des Blutsaugens aufnehmen, das Spirochäteninokulum vor Übertragung auf den Wirt zu reduzieren vermögen. Derzeit werden zwei verschiedene rekombinante (monovalente) OspA-Impfstoffe in großen Phase-III-Studien in den Vereinigten Staaten erprobt. Lokale Beschwerden an der intramuskulären Injektionsstelle sind derzeit die wichtigsten Nebenwirkungen, die mit diesen Impfstoffen beobachtet werden, doch werden weitere Daten zur Frage der Sicherheit erhoben. Lyme-Borrelien haben in Europa eine ausgeprägtere Heterogenität, deshalb müßte eine Vakzine dort mehrere Antigene enthalten (multivalente Vakzine). Dieses Problem trifft allerdings auch für die USA zu.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Centers for Disease Control and Prevention Lyme disease — United States, 1993. MMWR 43 (1994) 564, 565, 571.Google Scholar
  2. 2.
    Steere, A. C. Lyme disease. N. Engl. J. Med. 321 (1989) 586–596.Google Scholar
  3. 3.
    Steere, A. C., Taylor, E., McHugh, G. L., Logigian, E. L. The over diagnosis of Lyme disease. JAMA 269 (1993) 1812–1816.Google Scholar
  4. 4.
    Steere, A. C., Levin, R. E., Molloy, P. J., Kalish, R. A., Abraham, J. H. 3rd, Liu, N. Y., Schmid, C. H. Treatment of Lyme arthritis. Arthritis Rheum. 37 (1994) 878–888.Google Scholar
  5. 5.
    Edelman, R. Perspective on the development of vaccines against Lyme disease. Vaccine 9 (1991) 531–532.Google Scholar
  6. 6.
    Edelman, R. The Sixth International Conference on Lyme Borreliosis: Progress on the development of Lyme disease vaccines. Vaccine 113 (1995) 133–135.Google Scholar
  7. 7.
    Wormser, G. P. A vaccine against Lyme disease? Ann. Intern. Med. 123 (1995) 627–628.Google Scholar
  8. 8.
    Wormser, G. P. Prospects for a vaccine to prevent Lyme disease in humans. Clin. Infect. Dis. 21 (1995) 1267–1274.Google Scholar
  9. 9.
    Johnson, R. C., Kodner, C., Russell, M. Passive immunization of hamsters against experimental infection with Lyme disease spirochete. Infect. Immun. 53 (1986) 713–714.Google Scholar
  10. 10.
    Johnson, R. C., Kodner, C., Russell, M. Active immunization of hamsters against experimental infection withBorrelia burgdorferi. Infect. Immun. 54 (1986) 897–898.Google Scholar
  11. 11.
    Johnson, R. C., Kodner, C. L., Russell, M. E. Vaccination of hamsters against experimental infection withBorrelia burgdorferi. Zentralbl. Bakteriol. Mikrobiol. Hyg. Ser. A 263 (1986) 45–48.Google Scholar
  12. 12.
    Levy, S. A., Lissman, B. A., Ficke, C. M. Performance ofBorrelia burgdorferi bacterin in borreliosis-endemic areas. J. Am. Vet. Med. Assoc. 202 (1993) 1834–1838.Google Scholar
  13. 13.
    Chu, H.-J., Chavez, L. G. Jr., Blumer, B. M., Sebring, R. W., Wasmoen, T. L., Acree, W. M. Immunogenicity and efficacy study of a commercialBorrelia burgdorferi bacterin. J. Am. Vet. Med. Assoc. 201 (1992) 403–411.Google Scholar
  14. 14.
    Keller, D., Koster, F. T., Marks, D. H., Hosbach, P., Erdile, L. F., Mays, J. P. Safety and immunogenicity of recombinant outer surface protein A Lyme vaccine. JAMA 271 (1994) 1764–1768.Google Scholar
  15. 15.
    Szczepanski, A., Benach, J. L. Lyme borreliosis: Host responses toBorrelia burgdorferi. Microbiol. Rev. 55 (1991) 21–34.Google Scholar
  16. 16.
    Sigal, L. G., Tatum, A. H. Lyme disease patients' serum contains IgM antibodies toBorrelia burgdorferi that cross react with neuronal antigens. Neurology 38 (1988) 1439–1442.Google Scholar
  17. 17.
    Aberer, E., Brunner, C., Suchanek, G., Klade, H., Barbour, A., Stanek, G., Lassmann, H. Molecular mimicry and Lyme borreliosis: a shared antigenic determinant betweenBorrelia burgdorferi and human tissue. Ann. Neurol. 26 (1989) 732–737.Google Scholar
  18. 18.
    Sigal, L. H. Immunology of Lyme disease. N. Jersey. Med. 87 (1990) 567–571.Google Scholar
  19. 19.
    Fikrig, E., Berland, R., Chen, M., Williams, S., Sigal, L. T., Flavell, R. A. Serologic response to theBorrelia burgdorferi flagellin demonstrates an epitope common to a neuroblastoma cell line. Proc. Natl. Acad. Sci. 90 (1993) 183–187.Google Scholar
  20. 20.
    Preac Mursic, V., Wilske, B., Patsouris, F., Jauris, S., Will, G., Soutschek, E., Rainhardt, S., Lehnert, G., Kluckmann, U., Mehraein, P. Active immunization with pC protein ofBorrelia burgdorferi protects gerbils againstB. burgdorferi infection. Infection 20 (1992) 342–349.Google Scholar
  21. 21.
    Fikrig, E., Barthold, S. W., Marcantino, N., Deponte, K., Kantor, F. S., Flavell, R. A. Roles of OspA, OspB and flagellin in protective immunity to Lyme borreliosis in laboratory mice. Infect. Immun. 60 (1992) 657–661.Google Scholar
  22. 22.
    Probert, W. S., Lefebvre, R. B. Protection of C3H/HeN mice from challenge withBorrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Infect. immun. 62 (1994) 1920–1926.Google Scholar
  23. 23.
    Fikrig, E., Barthold, S. W., Kantor, F. S., Flavell, R. A. Protection of mice from Lyme borreliosis by oral vaccination withEscherichia coli expressing OspA. J. Infect. Dis. 164 (1991) 1224–1227.Google Scholar
  24. 24.
    Fikrig, E., Barthold, S. W., Kantor, F. S., Flavell, R. A. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science 250 (1990) 553–556.Google Scholar
  25. 25.
    Fikrig, E., Barthold, S. W., Kantor, F. S., Flavell, R. A. Long-term protection of mice from Lyme disease by vaccination with OspA. Infect. Immun. 60 (1992) 773–777.Google Scholar
  26. 26.
    Telford, S. R. III, Kantor, F. S., Lobet, Y., Barthold, S. W., Spielman, A., Flavell, R. A., Fikrig, E. Efficacy of human Lyme disease vaccine formulations in a mouse model. J. Infect. Dis. 171 (1995) 1368–1370.Google Scholar
  27. 27.
    Schaible, U. E., Wallich, R., Kramer, M. D., Gern, L., Anderson, J. F., Museteanu, C., Simon, M. M. Immune sera to individualBorrelia burgdorferi isolates or recombinant OspA thereof protect SCID mice against infection with homologous strains but only partially, or not at all against those of different OspA/OspB genotype. Vaccine 11 (1993) 1049–1054.Google Scholar
  28. 28.
    Schaible, U. E., Kramer, M. D., Eichmann, K., Modolell, M., Museteanu, C., Simon, M. M. Monoclonal antibodies specific for the outer surface protein A (OspA) ofBorrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (Scid) mice. Proc. Natl. Acad. Sci. 87 (1990) 3768–3772.Google Scholar
  29. 29.
    Fikrig, E., Bockenstedt, L. K., Barthold, S. W., Chen, M., Tao, H., Ali-Salaam, P., Telford, S. R., Flavell, R. A. Sera from patients with chronic Lyme disease protect mice from Lyme borreliosis. J. Infect. Dis. 169 (1994) 568–574.Google Scholar
  30. 30.
    Sears, J. E., Fikrig, E., Nakagawa, T. Y., Deponte, K., Marcantino, N., Kantor, F. S., Flavell, R. A. Molecular mapping of OspA mediated immunity againstBorrelia burgdorferi the agent of Lyme disease. J. Immunol. 147 (1991) 1995–2000.Google Scholar
  31. 31.
    Sadziene, A., Thompson, P. A., Barbour, A. G. In vitro inhibition ofBorrelia burgdorferi growth by antibodies. J. Infect. Dis. 167 (1993) 165–172.Google Scholar
  32. 32.
    Pavia, C. S., Kissel, V., Bittker, S., Cabello, F., Levine, S. Antiborrelial activity of serum from rats injected with the Lyme disease spirochete. J. Infect. Dis. 163 (1991) 656–659.Google Scholar
  33. 33.
    Montgomery, R. R., Nathanson, M. H., Malawista, S. E. Fc and non-Fc-mediated phagocytosis ofBorrelia burgdorferi by macrophages. J. Infect. Dis. 170 (1994) 890–893.Google Scholar
  34. 34.
    Benach, J. L., Fleit, H. B., Habicht, G. S., Coleman, J. L., Bosler, E. M., Lane, B. P. Interactions of phagocytes with the Lyme disease spirochete: role of the Fc receptor. J. Infect. Dis. 150 (1984) 497–507.Google Scholar
  35. 35.
    Comstock, L. E., Thomas, D. D. Characterization ofBorrelia burgdorferi invasion of cultured endothelial cells. Microbiol. Pathog. 10 (1991) 137–148.Google Scholar
  36. 36.
    Comstock, L. E., Thomas, D. D. Penetration of endothelial cell monolayers byBorrelia burgdorferi. Infect. Immun. 57 (1989) 1626–1628.Google Scholar
  37. 37.
    Wilske, B., Barbour, A. G., Bergstrom, S., Burman, N., Restrapo, B. I., Rose, P. A., Schwan, T., Soutschek, E., Wallich, R. Antigenic variation and strain heterogeneity inBorrelia spp. Res. Microbiol. 143 (1992) 583–596.Google Scholar
  38. 38.
    Dykhuizen. D. E., Polin, D. S., Dunn, J. J., Wilske, B., Preac-Mursic, V., Dattwyler, R. J., Luft, E. J. Borrelia burgdorferi is clonal: implications for taxonomy and vaccine development. Proc. Natl. Acad. Sci. 90 (1993) 10163–10167.Google Scholar
  39. 39.
    Lovrich, S. D., Callister, S. M., Lim, L. C. L., DuChateau, B. K., Schell, R. F. Seroprotective groups of Lyme borreliosis spirochetes from North America and Europe. J. Infect. Dis. 170 (1994) 115–121.Google Scholar
  40. 40.
    Macroni, R. T., Garon, C. F. Phylogenetic analysis of the genusBorrelia: a comparison of North American and European isolates ofBorrelia burgdorferi. J. Bacteriol. 174 (1992) 241–244.Google Scholar
  41. 41.
    Fikrig, E., Barthold, S. W., Persing, D. H., Sun, X., Kantor, F. S., Flavell, R. A. Borrelia burgdorferi strain 25015: characterization of outer surface protein A and vaccination against infection. J. Immunol. 148 (1992) 2256–2260.Google Scholar
  42. 42.
    Fikrig, E., Telford, S. R. III, Wallich, R., Chan, M., Lobat, Y., Matuschka, F. R., Kimsey, R. B., Kantor, F. S., Barthold, S. W., Spielman, A., Flavell, R. A. Vaccination against Lyme disease caused by diverseBorrelia burgdorferi. J. Exp. Med. 181 (1995) 215–221.Google Scholar
  43. 43.
    Telford, S. R. III, Fikrig, E., Barthold, S. W., Brunet, L. R., Spielman, A., Flavell, R. A. Protection against antigenically variableBorrelia burgdorferi conferred by recombinant vaccines. J. Exp. Med. 178 (1993) 755–758.Google Scholar
  44. 44.
    Fikrig, E., Telford, S. R. III, Barthold, S. W., Kantor, F. S., Spielman, A., Flavell, R. A. Elimination ofBorrelia burgdorferi from vector ticks feeding on OspA immunized mice. Proc. Natl. Acad. Sci. 89 (1992) 5418–5421.Google Scholar
  45. 45.
    Shih, C.-M., Spielman, A., Telford, S. R. III Short report: mode of action of preventive immunity to Lyme disease spirochetes. Am. J. Trop. Med. Hyg. 52 (1995) 72–74.Google Scholar
  46. 46.
    Piesman, J., Mather, T. N., Sinsky, R. J., Spielman, A. Duration of a tick attachment andBorrelia burgdorferi transmission. J. Clin. Microbiol. 25 (1987) 557–558.Google Scholar
  47. 47.
    Piesman, J. Dynamics ofBorrelia burgdorferi transmission by nymphalIxodes dammini ticks. J. Infect. Dis. 167 (1993) 1082–1085.Google Scholar
  48. 48.
    Stover, C. K., Bansal, G. P., Hanson, M. S., Burlain, J. E., Palaszynski, S. R., Young, J. F., Koenig, S., Young, D. B., Sadziene, A., Barbour, A. G. Protective immunity elicited by recombinant Bacille Calmette-Guérin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J. Exp. Med. 178 (1993) 197–209.Google Scholar
  49. 49.
    VanHoecke, C., DeGrave, D., Hauser, P., Lebacq, E.: Evaluation of three formulations of a candidate vaccine against Lyme disease in healthy adult volunteers. VI International Conference on Lyme Borreliosis, Bologna, Italy, June 1994, #014M.Google Scholar
  50. 50.
    Marks, D. H., Hosbach, P., Koster, F., Wormser, G., Bryant, G., Gwaltney, J., Froeschle, J., Erdile, L., Mays, J.: Clinical studies in humans of outer surface protein A (OspA) vaccine for Lyme disease. VI International Conference on Lyme Borreliosis, Bologna, Italy, June 1994, #015.Google Scholar
  51. 51.
    VanHoecke, C., Voet, P., DeGrove, D., Hansen, P.: Immunogenicity of Al(OH)3-adsorbed and plain lipoprotein OspA vaccine formulation in monkeys and man. 34th Interscience Conference on Antimicrobial Agents Chemotherapy, Orlando, Florida, October 4–7, 1994.Google Scholar
  52. 52.
    Craft, J. E., Fischer, D. K., Schimato, G. T., Steere, A. C. Antigens ofBorrelia burgdorferi recognized during Lyme disease. Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness. J. Clin. Invest. 78 (1986) 934–939.Google Scholar
  53. 53.
    Kalish, K. R. A., Leong, J. M., Steere, A. C. Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB ofBorrelia burgdorferi. Infect. Immun. 167 (1993) 971–975.Google Scholar
  54. 54.
    Lengl-Janben, B., Strauss, A. F., Steere, A. C., Komradt, T. The T helper cell response in Lyme arthritis: differential recognition ofBorrelia burgdorferi outer surface protein A in patients with treatment-resistant or treatment-responsive Lyme arthritis. J. Exp. Med. 180 (1994) 2069–2078.Google Scholar

Copyright information

© MMV Medizin Verlag GmbH München 1996

Authors and Affiliations

  • G. P. Wormser
    • 1
  1. 1.Division of Infectious Diseases, Room 209 SE, Macy PavilionWestchester County Medical CenterValhallaUSA

Personalised recommendations